Menu
Karolinska Development
Transaction Overview
In February 2013, Rosetta Capital completed a secondary transaction to acquire a portfolio of thirteen life sciences assets from Karolinska Development, the investment arm of Karolinska Institutet, a leading university in Sweden.
The sale portfolio consists of holdings in Akinion Pharmaceuticals, Aprea Therapeutics, Axelar, Biosergen, Clanotech, Dilafor, Inhalation Sciences, NeoDynamics, NovaSAID, Pergamum, Promimic, and Umecrine Mood.
The sale portfolio consists of holdings in Akinion Pharmaceuticals, Aprea Therapeutics, Axelar, Biosergen, Clanotech, Dilafor, Inhalation Sciences, NeoDynamics, NovaSAID, Pergamum, Promimic, and Umecrine Mood.
Supporting portfolio companies for the next growth phase
Rosetta Capital is committed to supporting the portfolio companies acquired in the transaction through the growth phase and has made several follow-on investments.
Rosetta partners have joined the boards of acquired portfolio companies and are actively involved in strategic decision making.
Rosetta partners have joined the boards of acquired portfolio companies and are actively involved in strategic decision making.
